Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in Kenya
View/ Open
Date
2009Author
Jaoko Walter G
OGUTU, H.
WAKASIAKA, S.
MALOGO, R.
NDAMBUKI, R.
NYANGE, J.
OMOSA-MANYONYI, G.
FAST, P.
SCHMIDT, C.
VERLINDE, C.
SMITH, C.
BHATT, KM.
Ndinya-Achola, JO
ANZALA, O.
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Female participants in AIDS candidate vaccine clinical trials must agree to use effective contraception to be enrolled into the studies, and for a specified period after vaccination, since the candidate vaccines’ effects on the embryo or foetus are unknown.country settings. Effective female-controlled contraceptives, administered at the clinical trial site, may empower female participants to better control their fertility, leading to more complete clinical trial data.
URI
http://www.ncbi.nlm.nih.gov/pubmed/21644413http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10067
Citation
East African Medical JournalCollections
- Faculty of Health Sciences (FHS) [10377]